Core Viewpoint - The company reported a significant decline in revenue and profit for the fiscal year ending December 31, 2023, primarily due to reduced demand for COVID-19 related services, although there is a recovery in non-COVID-19 testing services following the lifting of restrictions [1]. Financial Performance - The company achieved revenue of 3.298 billion RMB, a year-on-year decrease of 32.15% [1]. - Profit attributable to equity holders of the parent company was 235 million RMB, down 65.5% year-on-year [1]. - Basic earnings per share were 0.34 RMB [1]. Gross Margin Analysis - The overall gross margin for the fiscal year was 43.5%, compared to 39.0% for the previous year [1]. - The increase in gross margin was attributed to a decrease in raw material costs compared to 2022, various cost control measures implemented in 2023, and a shift towards higher-margin specialized tests [1].
艾迪康控股(09860)发布2023年度业绩 股东应占溢利2.35亿元 同比减少65.5%